The Global Neurodegeneration Proteomics Consortium (GNPC), a public-private partnership established by Janssen Research & Development LLC and Gates Ventures in 2023, has announced the release of the first GNPC dataset, via the Alzheimer’s Disease Data Initiative’s AD Workbench. The dataset includes approximately 250 million protein measurements from nearly 35,000 plasma, serum and cerebrospinal fluid samples contributed by 23 neurodegeneration research cohorts. These samples are linked to harmonised clinical, demographic and cognitive data from participants with Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and amyotrophic lateral sclerosis, among other neurodegenerative conditions. Participating cohorts include the Swedish BioFINDER study, Imperial College’s CHARIOT-PRO study (UK), the international Parkinson’s Progression Markers Initiative, together with others from the Netherlands, Spain, Sweden and US.
Most samples were analysed using the SomaScan 7k proteomics platform, and a subset have additional validation using mass spectrometry and other assays. Over 40% of samples are longitudinal, supporting the study of within-individual biological changes over time. Members of the global research community can request access to the dataset through the AD Workbench, which is a cloud-based data platform that provides researchers with secure, remote access to large datasets from cohorts studying Alzheimer’s disease and other neurodegenerative disorders. By enabling comparisons across diseases, study designs and geographies, the GNPC datast supports efforts to identify disease mechanisms, new biomarkers and potential therapeutic targets. This may ultimately help improve diagnostic accuracy, inform clinical trial recruitment and guide treatment selection, particularly for conditions with overlapping or mixed pathologies. The public release of GNPC version 1 is accompanied by a set of peer-reviewed publications in Nature Medicine, which describe the consortium, methods, initial analyses and early findings.
These articles can be accessed at the following links:
https://www.nature.com/articles/s41591-025-03834-0
https://www.nature.com/articles/s41591-025-03833-1
https://www.nature.com/articles/s41591-025-03831-3 https://www.nature.com/articles/s41591-025-03835-z
A second version of the dataset, including new biosamples, platforms and expanded metadata, is under development.
